Over the last 7 days, the United States market has experienced a 1.4% decline, but it has shown resilience with a 17% rise over the past year and anticipated earnings growth of 18% per annum in the coming years. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for revenue expansion and innovation, aligning well with current market conditions.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
AppLovin	21.14%	21.74%	★★★★★★
Seagate Technology Holdings	24.63%	37.74%	★★★★★★
Krystal Biotech	29.70%	36.60%	★★★★★★
Lumentum Holdings	42.82%	56.30%	★★★★★★
Ardelyx	24.57%	55.92%	★★★★★★
AnaptysBio	20.47%	48.14%	★★★★★★
Marker Therapeutics	64.28%	69.04%	★★★★★★
Madrigal Pharmaceuticals	28.73%	59.11%	★★★★★★
Syndax Pharmaceuticals	28.34%	68.06%	★★★★★★
Travere Therapeutics	23.28%	49.02%	★★★★★★

Here's a peek at a few of the choices from the screener.

Ardelyx (ARDX)

Simply Wall St Growth Rating: ★★★★★★

Overview: Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines to address unmet medical needs globally, with a market cap of approximately $1.28 billion.

Operations: Ardelyx generates revenue primarily through the development and commercialization of biopharmaceutical products, totaling $427.68 million. The company operates both in the United States and internationally, addressing significant unmet medical needs.

Ardelyx's recent strides, particularly with its innovative product XPHOZAH, underscore its potential within the high-growth tech segment of biopharmaceuticals. At recent conferences and through pivotal studies, Ardelyx showcased XPHOZAH's effectiveness in managing serum phosphate in CKD patients on dialysis—a market that affects nearly 550,000 U.S. patients annually. With a reported 24.6% annual revenue growth and an anticipated profitability surge by 55.9% per year, Ardelyx is setting a robust pace in its sector. The company’s focus on specialized treatment for hyperphosphatemia positions it well for future growth amidst evolving healthcare demands.

AnaptysBio (ANAB)

Simply Wall St Growth Rating: ★★★★★★

Overview: AnaptysBio, Inc. is a clinical-stage biotechnology company that specializes in developing immunology therapeutics for autoimmune and inflammatory diseases in the United States, with a market cap of approximately $1.72 billion.

Operations: AnaptysBio focuses on developing immunology therapeutics targeting autoimmune and inflammatory diseases. The company operates as a clinical-stage biotechnology firm, with its financial performance largely driven by research and development activities rather than revenue generation at this stage.

AnaptysBio, despite recent exclusion from key indexes, shows promising financial and operational metrics. The company's projected annual revenue growth at 20.5% and earnings surge by 48.14% annually highlight its potential in the biotech sector. Moreover, AnaptysBio's strategic sublease agreement with First Tracks Biotherapeutics not only optimizes its real estate assets but also secures a steady income stream over the next year, enhancing its financial stability. This move, coupled with a robust forecasted Return on Equity of 124.5%, positions AnaptysBio to capitalize on future biotechnological advancements and market demands effectively.

Syndax Pharmaceuticals (SNDX)

Simply Wall St Growth Rating: ★★★★★★

Overview: Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing cancer therapies, with a market cap of $2.02 billion.

Operations: Syndax Pharmaceuticals generates revenue primarily from its biotechnology segment, which focuses on startups and reported $217.17 million in revenue. The company is engaged in developing cancer therapies as part of its commercial-stage operations.

Syndax Pharmaceuticals, recently excluded from key indexes, demonstrates robust growth prospects with a forecasted 28.3% annual revenue increase and an expected earnings growth of 68.1%. The company's innovative R&D strategy is underscored by the development of SNDX-4321, a novel EGFR inhibitor targeting specific NSCLC mutations, reflecting a strategic shift towards targeted cancer therapies with high unmet needs. This focus on precision medicine is complemented by their upcoming IND submissions and Phase 1 trials, positioning Syndax to potentially reshape treatment paradigms in oncology.

Summing It All Up

• Click this link to deep-dive into the 17 companies within our US High Growth Tech and AI Stocks screener.
• Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
• Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.

Interested In Other Possibilities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.